Receipt of perioperative blood transfusion after surgery for renal cell carcinoma is associated with a higher risk of tumor recurrence, progression, and death. READ MORE
Cabozantinib improves progression-free survival in patients with advanced renal cell carcinoma, according to an ongoing clinical trial.
Receipt of perioperative blood transfusion after surgery for renal cell carcinoma is associated with a higher risk of tumor recurrence, progression, and death.
The National Comprehensive Cancer Network recently issued an updated version of their guidelines for varying histologies of kidney cancer.
Some health care services are rarely offered among older patients in the perioperative period for kidney cancer.
Genetic variants that predispose individuals to longer telomere length appear to be associated with an increased risk of renal-cell carcinoma.
Research in Review
Stereotactic ablative radiation therapy can achieve more than 90% control of renal cell carcinoma metastases.
Patients with renal cell carcinoma who have surgery to remove metastatic tumors are likely to double their life expectancy.
Primary non-small cell lung cancer (NSCLC) may be underdiagnosed in patients with metastatic renal cell carcinoma, according to new research.
First-line therapy with cabozantinib was superior to standard of care sunitinib with respect to progression-free survival and objective response rate for patients with intermediate- or poor-risk metastatic renal cell carcinoma, according to a study published in the Journal of Clinical Oncology.